Search Results - gag

4 Results

Sort By:

Vaccines for HIV

Abstract: The development of an effective HIV vaccine has been an ongoing area of research. The high variability in HIV-1 virus strains has represented a major challenge in successful development. Ideally, an effective candidate vaccine would provide protection against the majority of clades of HIV. Two major hurdles to overcome are immunodominance...

Published: 5/22/2024 | Inventor(s): Barbara Felber, George Pavlakis, Antonio Valentin, James Mullins

Keywords(s): ENV, GAG, HIV Vaccine, immunogenic conserved elements

Category(s): Collaboration Sought > Collaboration, Application > Vaccines, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease

Combined RNA and DNA Vaccination Strategy for Improving the Vaccine Immune Response

The development of an effective HIV vaccine has been ongoing. HIV sequence diversity and immunodominance are major obstacles in the design of an effective vaccine. Researchers at the National Cancer Institute (NCI) developed a novel vaccine strategy combining both DNA and mRNA vaccination to induce an effective immune response. This combination strategy...

Published: 5/22/2024 | Inventor(s): Barbara Felber, George Pavlakis

Keywords(s): CANCER VACCINE, DNA vaccine, ENV, Felber, GAG, HIV, Infectious Disease, Nci, Pavlakis, RNA Vaccine, SARS-CoV-2, Vaccine

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Vaccines, TherapeuticArea > Infectious Disease

Chimeric SHIV Gag Proteins Optimize T-Cell Response Against HIV Gag

HIV Gag has been included in nearly all HIV vaccines entering clinical trials because of its importance in SIV models and its correlation with protection in HIV-infected long-term non-progressors. However, HIV Gag has proven less immunogenic than Env in phase I clinical trial studies. Through sequence comparison, two regions in HIV Gag have been identified...

Published: 7/25/2024 | Inventor(s): Gary Nabel

Keywords(s): Against, Cell, chimeric, DC5AXX, DC5XXX, DCXXXX, Development, Duke DNA Project, DXXXXX, Filovirus, GAG, HIV, HIV/SIV, Infection, Optimize, PREVENTIVE, primate, proteins, Responses, T, Vaccine, Vaccine-Induced

Category(s): Collaboration Sought > Licensing, Application > Vaccines, TherapeuticArea > Infectious Disease

MVA Expressing Modified HIV envelope, gag, and pol Genes

This invention claims Modified Vaccinia Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing Human Immunodeficiency Virus (HIV) env, gag, and pol genes, where the genes are isolated from Ugandan Clade D isolates, Kenyan Clade A isolates, and Tanzanian Clade C isolates. In a rhesus macaque SHIV model, DNA priming followed by a...

Published: 7/25/2024 | Inventor(s): Linda Wyatt, Patricia Earl, Bernard Moss

Keywords(s): (4)r syndrome, 3-@hydroxyacyl-coa dehydrogenase deficiency, Altered, C syndrome, Chromosome 4 ring syndrome, Chromosome 6 ring syndrome, Chromosome 7 ring syndrome, D, DB4AXX, DB4XXX, DBXXXX, DC5AXX, DC5XXX, DCXXXX, DXXXXX, Envelope, Expressing, G syndrome, GAG, GENES, HAD deficiency, HIS deficiency, Histidinemia, HIV, Hyper IgM syndrome, Hypertelorism with esophageal abnormality and hypospadias, Immunodeficiency 2, Immunodeficiency 4, Immunodeficiency-3, MVA, N syndrome, polymerase, R(6) syndrome, R(7) syndrome, Severe combined immunodeficiency, x-linked, Subtype, Syndrome X, W syndrome, W syndrome; Syndrome W, Wiskott Aldrich syndrome

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease, Application > Vaccines